VRDN
NASDAQ · Biotechnology
Viridian Therapeutics Inc
$17.32
+0.04 (+0.23%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
-45.67%
1Y
+18.14%
YTD
-43.55%
Open$17.50
Previous Close$17.28
Day High$17.78
Day Low$17.16
52W High$34.29
52W Low$13.18
Volume—
Avg Volume1.73M
Market Cap1.84B
P/E Ratio—
EPS$-3.96
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$31.51
Below
SMA 200
$22.43
Below
RSI (14)
17.6
Oversold
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
23 analysts
Price Target
+268.6% upside
Current
$17.32
$17.32
Target
$63.84
$63.84
$43.31
$63.84 avg
$68.31
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 92.26M | 891.8K | 430.67M |
| Net Income | -446,116,804 | -725,406,968 | -19,976,292 |
| Profit Margin | -483.6% | -84,917.7% | -4.6% |
| EBITDA | -472,553,192 | -846,793,579 | -30,128,222 |
| Free Cash Flow | — | — | -23,390,816 |
| Rev Growth | +242.1% | -53.3% | -2.2% |
| Debt/Equity | 0.12 | 0.03 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |